Alzeca Biosciences raised $11 million to develop its nanoparticle contrast agent, designed for the early detection of Alzheimer’s disease.
VentureMed Group raised $15 million to support R&D, clinical trials and expand the sales team for its PAD treatment catheter.
RBM is, above all, an opportunity to practice mindfulness in collecting clinical trial data within the site- and patient-centric environment.
Consultancy-cum-VC Genesis Innovation has raised cash to back medical device startups.
NeoSync raised $13 million for a registration trial of its magnetic stimulation technology in treatment-resistant depression.
Osprey Medical has raised $17.5 million for its device that makes a heart procedure safer for patients with chronic kidney disease.
Neuros Medical raised $20 million to complete the pivotal study of its neuromodulation device for postamputation pain.
Karius raised $50 million to boost clinical trials and commercialization of its blood-based test that detects more than 1,250 pathogens.
Viome raised $15 million for its microbiome-sequencing platform, which uses machine learning to help patients avoid chronic disease.
Sebacia raised $36 million to complete the U.S. pivotal trial of its gold-and-silica microparticle acne treatment.
The series B round equips Amphora to take its minimally invasive, cystoscopic device into the last step of clinical development next year.